Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predictive Value of Combined Criteria to Tailor Breast Cancer Screening and New Opportunities From Circulating Markers. The Andromeda Study.

NCT02618538 is registered in ClinicalTrials.gov with Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte as lead sponsor.

NCT NCT02618538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02618538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predictive Value of Combined Criteria to Tailor Breast Cancer Screening and New Opportunities From Circulating Markers. The Andromeda Study.
Lead sponsor
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
Phase
Observational
Overall status
Completed
Start date
July 31, 2015
Completion date
March 31, 2018
Enrollment
26,600 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer